PTC-028 is a small molecule degrader of BMI1 (B-cell-specific Moloney murine leukemia virus integration site 1), an epigenetic regulator that promotes cancer stem cell maintenance, tumor growth, and resistance to therapy. It is primarily investigated for its potential in cancer therapy, particularly in targeting BMI1 to disrupt pathways involved in cell proliferation, self-renewal, and survival. By inducing BMI1 degradation, PTC-028 promotes differentiation and apoptosis in cancer cells, making it a promising candidate for treating various solid tumors, including small cell lung cancer and other malignancies resistant to conventional treatments. Researchers are exploring its efficacy in preclinical models, along with its pharmacokinetic properties and safety profile, to assess suitability for clinical trials. Its role in overcoming drug resistance by eliminating cancer stem cells offers hope for improved outcomes in challenging cancer cases.